CohBar adds Dr. Joanne Yun to its Board as Independent Director

– USA, CA –  CohBar, Inc. (NASDAQ: CWBR), a clinical-stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment of Dr. Joanne Yun (Ph.D.) to its Board as an independent director, effective September 14, 2021.

Dr. Yun brings extensive research and development, commercial, and governance experience from the pharmaceutical industry.

“We are very pleased to add Dr. Yun as an independent director and look forward to her strategic input as we continue to develop our diverse pipeline of novel mitochondria based therapeutics,” said Board Chairman, David Greenwood. “Joanne has a wealth of industry experience with a large, impressive network. Her deep understanding of the biotechnology and pharmaceutical industries will provide significant contributions.”


Dr. Yun is a partner at Egon Zehnder, one of the world’s preeminent leadership advisory firms, and is currently a member of the firm’s Health Practice. In addition to her board and executive leadership work for global pharmaceutical and biotechnology companies, Dr. Yun leads the Research & Development segment of Egon Zehnder’s Health Practice.

Before joining Egon Zehnder, Dr. Yun was a Director in the Global Oncology Business Unit for Bayer HealthCare Pharmaceuticals with responsibility for oncology program management and new product planning. She has advised on all aspects of research, development, and commercial strategies, including portfolio prioritization, business development, alliance governance, and merger integration. Dr. Yun started her career with Bayer AG as a Bench Chemist and Laboratory Head in the Organic Synthesis Department of Bayer’s Central Research Division in Leverkusen, Germany. She later transitioned into the Corporate Research & Development Planning Department for the Bayer AG Board of Management and then joined the Strategic Planning Department for the Pharmaceuticals Division, where she focused on global merger & acquisition strategies and transactions. Dr. Yun subsequently transferred to Bayer’s North America Business Development & Licensing group.

“I am quite excited to join CohBar’s Board and believe the company is well-positioned to address several important medical conditions in need of new therapies,” commented Dr. Yun. “CohBar’s unique approach to developing novel peptide therapeutics provides multiple independent opportunities for success, with the potential to make a real difference in the lives of patients. I look forward to working closely with the management team and the rest of the Board to advance the company’s pipeline and build on the recent success of the positive topline data from the CB4211 clinical trial.”

Dr. Yun earned a bachelor’s degree in chemistry and French from Amherst College and a Ph.D. in chemistry from the Massachusetts Institute of Technology. She was a National Institutes of Health Postdoctoral Fellow at The Scripps Research Institute and is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the American Chemical Society.

About CohBar

CohBar is a clinical-stage biotechnology company focused on the research and development of mitochondria-based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria-based therapeutics originate from the discovery by CohBar’s founders of a novel group of naturally occurring peptide sequences within the mitochondrial genome, some of which have been shown to have the potential to regulate key processes in multiple systems and organs in the body. To date, the company has discovered more than 100 mitochondrial-derived peptides and generated over 1,000 analogs. CohBar’s efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases associated with the underlying impact of mitochondrial dysfunction. The company’s lead compound, CB4211, which is under development for the treatment of NASH and obesity, recently completed a successful Phase 1a/1b clinical trial. In addition, CohBar has four preclinical programs, the most advanced of which is CB5138-3, a peptide with broad anti-fibrotic and anti-inflammatory properties. This program is currently in IND-enabling studies to file an IND and initiate the First-in-Human study in 2022 with an initial indication of idiopathic pulmonary fibrosis. The company also has a program in ARDS, including COVID-19 associated ARDS, as well as two peptide families with potential utility in treating various forms of cancer.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team